Journal article
Thrombolytics in Acute Ischaemic Stroke: A Guide to Patient Selection and Optimum Use
BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, Vol.13(2), pp.115-126
02/2000
DOI: 10.2165/00063030-200013020-00005
PMID: 18034518
Abstract
Intravenously administered alteplase (recombinant tissue plasminogen activator; rtPA) is the only medical treatment that has been approved for the management of acute ischaemic stroke. Although rtPA has demonstrated efficacy in improving outcomes of patients with a wide range of neurological impairments, it cannot be given with impunity. Thrombolytic therapy is associated with a considerable risk of intracranial bleeding that is likely to be catastrophic. Careful selection of patients to treat and intensive ancillary care are the keys for successful administration of rtPA. An algorithm for selection is based on the interval from the onset of stroke, history of recent medical illnesses or use of medications, findings of the medical and neurological examinations and the results of laboratory and brain imaging studies. Because rtPA must be given within 3 hours of onset of stroke, most patients cannot be treated. Thus, additional therapies are needed for treatment of patients with acute ischaemic stroke.
Details
- Title: Subtitle
- Thrombolytics in Acute Ischaemic Stroke: A Guide to Patient Selection and Optimum Use
- Creators
- Harold Adams - Division of Cerebrovascular Diseases, Department of Neurology University of Iowa College of Medicine Iowa City Iowa USA
- Resource Type
- Journal article
- Publication Details
- BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, Vol.13(2), pp.115-126
- Publisher
- Springer International Publishing; Cham
- DOI
- 10.2165/00063030-200013020-00005
- PMID
- 18034518
- ISSN
- 1173-8804
- eISSN
- 1179-190X
- Language
- English
- Date published
- 02/2000
- Academic Unit
- Neurology; Iowa Neuroscience Institute
- Record Identifier
- 9984020772002771
Metrics
13 Record Views